Mangoceuticals, Inc. Common Stock
Here’s whether Mangoceuticals, Inc. Common Stock (MGRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.55% over 10 days); RSI 50 — healthy momentum range; 3-month momentum positive (+21.4%). Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -66.2%; declining volume on rally — weak conviction (0.73x 30d avg). Currently 80.6% off its 52-week high. Score: +0/7.
MGRX is trading below its 200-day MA ($0.63) — a key warning sign the longer-term trend is under pressure. An RSI of 49.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -66.2% compares to +20.4% for SPY (trailed the market by 86.5%). The current 80.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.